Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial
Allergy · 2025
DOI: 10.1111/all.70191 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2025. Verfasst von Alain Didier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie Allergologie and Réseau CRISALIS/F-CRIN INSERM, Hôpital Larrey, CHU de Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Poaceae, Allergens, Rhinitis, Allergic, Seasonal. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ALK-Abellό.
Abstract (Originalsprache)
Background
Tablet formulations of allergen extracts are widely recommended over other formulations for the sublingual immunotherapy (SLIT) of respiratory allergies. However, with adequate clinical trial evidence, SLIT (liquid) drop formulations may be a relevant allergy treatment option.
Methods
The RHAPSODY multinational, Phase III, parallel‐group, double‐blind, placebo‐controlled, randomised clinical study of adults with moderate‐to‐severe, grass‐pollen‐induced allergic rhinoconjunctivitis (ARC) with or without asthma was conducted at 45 investigating centres in six European countries. Participants received 26 months of continuous treatment with active 5‐grass‐pollen SLIT drops or placebo. The primary efficacy endpoint was the average daily total combined score (TCS, comprising a symptom score and a rescue medication score) during the second peak grass pollen season (PGPS).
Results
Of the 445 randomised patients (mean ± standard deviation (range) age: 32.6 ± 9.9 (18–63); males: 55.1%), 389 completed the trial. The primary efficacy endpoint showed a statistically significant difference in favour of active treatment versus placebo (average difference in the daily TCS: 1.88 (95% CI: 0.60–3.17); relative difference 26.51% (95% CI: 9.42–40.55); p = 0.0036). The difference (0.17 points) in the average weekly Rhinitis Quality of Life Questionnaire score during the second PGPS in favour of the active treatment was clinically relevant but not statistically significant. The differences in efficacy were generally driven by the medication score, rather than the symptom score. Most adverse events were mild and local.
Conclusions
RHAPSODY was the first well‐powered clinical trial to show the positive risk–benefit ratio of 5‐grass‐pollen SLIT drops in adult participants with moderate‐to‐severe grass‐pollen‐induced ARC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Pneumologie Allergologie and Réseau CRISALIS/F-CRIN INSERM, Hôpital Larrey, CHU de Toulouse, Toulouse, France.
- ALK-Abellό A/S, Hørsholm, Denmark.
- ALK France, Paris la défense, France.
- Department of Airway Diseases, Université de Versailles Saint-Quentin, Hôpital Foch, Suresnes, France.
ORCID-Profile: Alain Didier
Förderung
- ALK-Abellό
Zitieren
APA
Didier, A., Juhl, R. G., Dalgaard, T., Chartier, A., & Devillier, P. (2025). Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial. Allergy. https://doi.org/10.1111/all.70191
Vancouver
Didier A, Juhl RG, Dalgaard T, Chartier A, Devillier P. Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial. Allergy. 2025. doi:10.1111/all.70191
BibTeX
@article{Didier2025,
author = {Didier, Alain and Juhl, Ruta Gronskyte and Dalgaard, Terrie and Chartier, Antoine and Devillier, Philippe},
title = {Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.70191}
}
EUVIMED